Focal segmental glomerulosclerosis 4, susceptibility to

This study tests an injectable drug called AZD2373 in 136 people with APOL1-mediated kidney disease, a genetic condition that mainly affects people of African descent. The goal is to see if the drug can reduce protein leakage into urine, a sign of kidney damage. Participants will…

This study tests an experimental drug called VX-147 in adults and children with a genetic form of kidney disease linked to the APOL1 gene. The goal is to see if the drug can reduce protein in the urine and protect kidney function. About 466 participants will receive either VX-147…

This study tests an experimental drug called MZE829 in 56 adults with chronic kidney disease caused by a specific genetic risk (APOL1). The goal is to see if the drug can safely reduce protein leakage into urine, a sign of kidney damage. Participants will take the drug for 12 wee…

This study aims to better understand and treat people with certain inherited metabolic or genetic disorders. Researchers will use standard medical tests like blood work and imaging to diagnose and care for participants, who may also join other related studies. The goal is to expa…

This study is testing a new online platform called Nest for young adults aged 18-39 who have had genetic testing for cancer risk. The platform gives both patients and their doctors access to updated information about genetic findings. Researchers want to see if the tool is easy t…

This study from St. Jude Children's Research Hospital looks at how parents and children (ages 10-24) talk about the child's genetic risk for cancer. The goal is to understand what helps or hinders these conversations, so doctors can create better education programs. The study wil…

This study compares two ways to provide pre-test genetic counseling to people at high risk for hereditary cancers: a chatbot (Genetic Information Assistant) versus a live telegenetics session with a genetic counselor. About 96 participants will be randomly assigned to one method,…